Kawasaki Setsubi Kogyo Co., Ltd. (XNGO:1777)
Japan · Delayed Price · Currency is JPY 1,985.00
+35.00 (1.79%)
At close: Aug 8, 2025
Inozyme Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 33,600 | 29,159 | 22,482 | 20,809 | 23,604 | 21,894 | Upgrade |
Revenue Growth (YoY) | 47.47% | 29.70% | 8.04% | -11.84% | 7.81% | -5.32% | Upgrade |
Cost of Revenue | 26,893 | 23,776 | 18,881 | 17,606 | 20,252 | 18,897 | Upgrade |
Gross Profit | 6,707 | 5,383 | 3,601 | 3,203 | 3,352 | 2,997 | Upgrade |
Selling, General & Admin | 2,317 | 2,265 | 1,871 | 1,857 | 1,806 | 1,670 | Upgrade |
Research & Development | 4 | 4 | 8 | 11 | 10 | 10 | Upgrade |
Other Operating Expenses | 106 | 106 | 106 | 84 | 75 | 91 | Upgrade |
Operating Expenses | 2,722 | 2,670 | 2,267 | 2,162 | 2,083 | 1,926 | Upgrade |
Operating Income | 3,985 | 2,713 | 1,334 | 1,041 | 1,269 | 1,071 | Upgrade |
Interest Expense | -2 | -2 | -1 | -1 | -1 | - | Upgrade |
Interest & Investment Income | 10 | 7 | 6 | 6 | 4 | 3 | Upgrade |
Other Non Operating Income (Expenses) | 19 | 14 | 14 | 20 | 6 | 20 | Upgrade |
EBT Excluding Unusual Items | 4,012 | 2,732 | 1,353 | 1,066 | 1,278 | 1,094 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 13 | Upgrade |
Gain (Loss) on Sale of Assets | -1 | -1 | - | 8 | 7 | - | Upgrade |
Asset Writedown | -41 | -41 | - | - | - | - | Upgrade |
Pretax Income | 3,970 | 2,690 | 1,353 | 1,074 | 1,285 | 1,107 | Upgrade |
Income Tax Expense | 1,121 | 732 | 508 | 367 | 435 | 358 | Upgrade |
Net Income | 2,849 | 1,958 | 845 | 707 | 850 | 749 | Upgrade |
Net Income to Common | 2,849 | 1,958 | 845 | 707 | 850 | 749 | Upgrade |
Net Income Growth | 212.05% | 131.72% | 19.52% | -16.82% | 13.48% | -34.18% | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade |
EPS (Basic) | 238.13 | 163.66 | 70.63 | 59.09 | 71.05 | 62.60 | Upgrade |
EPS (Diluted) | 238.13 | 163.66 | 70.63 | 59.09 | 71.05 | 62.60 | Upgrade |
EPS Growth | 212.05% | 131.72% | 19.52% | -16.82% | 13.48% | -34.18% | Upgrade |
Free Cash Flow | - | -30 | -626 | 998 | 2,327 | 1,708 | Upgrade |
Free Cash Flow Per Share | - | -2.51 | -52.32 | 83.42 | 194.50 | 142.76 | Upgrade |
Gross Margin | 19.96% | 18.46% | 16.02% | 15.39% | 14.20% | 13.69% | Upgrade |
Operating Margin | 11.86% | 9.30% | 5.93% | 5.00% | 5.38% | 4.89% | Upgrade |
Profit Margin | 8.48% | 6.71% | 3.76% | 3.40% | 3.60% | 3.42% | Upgrade |
Free Cash Flow Margin | - | -0.10% | -2.78% | 4.80% | 9.86% | 7.80% | Upgrade |
EBITDA | 4,258 | 2,986 | 1,607 | 1,280 | 1,472 | 1,248 | Upgrade |
EBITDA Margin | 12.67% | 10.24% | 7.15% | 6.15% | 6.24% | 5.70% | Upgrade |
D&A For EBITDA | 273 | 273 | 273 | 239 | 203 | 177 | Upgrade |
EBIT | 3,985 | 2,713 | 1,334 | 1,041 | 1,269 | 1,071 | Upgrade |
EBIT Margin | 11.86% | 9.30% | 5.93% | 5.00% | 5.38% | 4.89% | Upgrade |
Effective Tax Rate | 28.24% | 27.21% | 37.55% | 34.17% | 33.85% | 32.34% | Upgrade |
Advertising Expenses | - | 31 | 18 | 20 | 18 | 11 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.